Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049716774> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2049716774 endingPage "740" @default.
- W2049716774 startingPage "737" @default.
- W2049716774 abstract "We aimed to see if structured treatment interruption (STI) could be supported safely with the use of two cycles of IL-2 (4.5 MIU q12h subcutaneously 5 days) before STI to prolong the time before therapy restarted.Subjects were randomly allocated to either A - continuous ART; B - continue for 9 weeks, then STI; restart with the same ART when the CD4 count falls below 200 cells; or C - two cycles of IL-2, 8 weeks apart, while still on ART; at week 9 stop ART and use a new cycle of IL-2 alone whenever the CD4 count falls < 300 cells. Patients were followed until week 105.86 mostly white middle aged homosexual men with a baseline median CD4 count of 754 cells/ml (range 240-1400) and a nadir CD4 count of 268 cells/ml (range 62-822) enrolled. By 96 weeks there was a 66% probability of having restarted ART in arm B compared with 34% in arm C (p = 0.002; log rank test). New drugs were used in 60% in arm A, 57% in arm B and 45% in arm C. 4 subjects had a dose modification in the first cycle due to toxicity with 2 interrupting. There were 39 SAEs with 21 in arm C. There were no deaths.The primary aim of the trial was to gain experience in using IL-2. IL-2 delayed restarting drugs and fewer new drugs were used." @default.
- W2049716774 created "2016-06-24" @default.
- W2049716774 creator A5004174170 @default.
- W2049716774 creator A5015402059 @default.
- W2049716774 creator A5016215468 @default.
- W2049716774 creator A5017386021 @default.
- W2049716774 creator A5027564673 @default.
- W2049716774 creator A5028130303 @default.
- W2049716774 creator A5047374087 @default.
- W2049716774 creator A5048403813 @default.
- W2049716774 creator A5050538872 @default.
- W2049716774 creator A5065768749 @default.
- W2049716774 creator A5078129526 @default.
- W2049716774 creator A5082016753 @default.
- W2049716774 date "2008-03-30" @default.
- W2049716774 modified "2023-09-22" @default.
- W2049716774 title "TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals" @default.
- W2049716774 cites W123672862 @default.
- W2049716774 cites W1497170016 @default.
- W2049716774 cites W1615721062 @default.
- W2049716774 cites W1965492966 @default.
- W2049716774 cites W1986036771 @default.
- W2049716774 cites W1995597879 @default.
- W2049716774 cites W2015688104 @default.
- W2049716774 cites W2073831371 @default.
- W2049716774 cites W2099564616 @default.
- W2049716774 cites W2126633107 @default.
- W2049716774 cites W2166670038 @default.
- W2049716774 doi "https://doi.org/10.1097/qad.0b013e3282f511f1" @default.
- W2049716774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18356603" @default.
- W2049716774 hasPublicationYear "2008" @default.
- W2049716774 type Work @default.
- W2049716774 sameAs 2049716774 @default.
- W2049716774 citedByCount "5" @default.
- W2049716774 countsByYear W20497167742012 @default.
- W2049716774 countsByYear W20497167742019 @default.
- W2049716774 crossrefType "journal-article" @default.
- W2049716774 hasAuthorship W2049716774A5004174170 @default.
- W2049716774 hasAuthorship W2049716774A5015402059 @default.
- W2049716774 hasAuthorship W2049716774A5016215468 @default.
- W2049716774 hasAuthorship W2049716774A5017386021 @default.
- W2049716774 hasAuthorship W2049716774A5027564673 @default.
- W2049716774 hasAuthorship W2049716774A5028130303 @default.
- W2049716774 hasAuthorship W2049716774A5047374087 @default.
- W2049716774 hasAuthorship W2049716774A5048403813 @default.
- W2049716774 hasAuthorship W2049716774A5050538872 @default.
- W2049716774 hasAuthorship W2049716774A5065768749 @default.
- W2049716774 hasAuthorship W2049716774A5078129526 @default.
- W2049716774 hasAuthorship W2049716774A5082016753 @default.
- W2049716774 hasBestOaLocation W20497167741 @default.
- W2049716774 hasConcept C126322002 @default.
- W2049716774 hasConcept C141071460 @default.
- W2049716774 hasConcept C142462285 @default.
- W2049716774 hasConcept C168563851 @default.
- W2049716774 hasConcept C197934379 @default.
- W2049716774 hasConcept C203014093 @default.
- W2049716774 hasConcept C29730261 @default.
- W2049716774 hasConcept C2993143319 @default.
- W2049716774 hasConcept C3013748606 @default.
- W2049716774 hasConcept C71924100 @default.
- W2049716774 hasConceptScore W2049716774C126322002 @default.
- W2049716774 hasConceptScore W2049716774C141071460 @default.
- W2049716774 hasConceptScore W2049716774C142462285 @default.
- W2049716774 hasConceptScore W2049716774C168563851 @default.
- W2049716774 hasConceptScore W2049716774C197934379 @default.
- W2049716774 hasConceptScore W2049716774C203014093 @default.
- W2049716774 hasConceptScore W2049716774C29730261 @default.
- W2049716774 hasConceptScore W2049716774C2993143319 @default.
- W2049716774 hasConceptScore W2049716774C3013748606 @default.
- W2049716774 hasConceptScore W2049716774C71924100 @default.
- W2049716774 hasIssue "6" @default.
- W2049716774 hasLocation W20497167741 @default.
- W2049716774 hasLocation W20497167742 @default.
- W2049716774 hasLocation W20497167743 @default.
- W2049716774 hasOpenAccess W2049716774 @default.
- W2049716774 hasPrimaryLocation W20497167741 @default.
- W2049716774 hasRelatedWork W2002120878 @default.
- W2049716774 hasRelatedWork W2003938723 @default.
- W2049716774 hasRelatedWork W2047967234 @default.
- W2049716774 hasRelatedWork W2118496982 @default.
- W2049716774 hasRelatedWork W2132697467 @default.
- W2049716774 hasRelatedWork W2439875401 @default.
- W2049716774 hasRelatedWork W3181939042 @default.
- W2049716774 hasRelatedWork W4238867864 @default.
- W2049716774 hasRelatedWork W4298264920 @default.
- W2049716774 hasRelatedWork W2525756941 @default.
- W2049716774 hasVolume "22" @default.
- W2049716774 isParatext "false" @default.
- W2049716774 isRetracted "false" @default.
- W2049716774 magId "2049716774" @default.
- W2049716774 workType "article" @default.